SCHEMBL6722753

SCHEMBL6722753

O=C(O)NC(C(=O)Nc1ccc2ccccc2c1)c1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.56
KMT2A Q03164 4/20 0.56
LMNA P02545 2/20 0.56
HTR1E P28566 1/20 0.56
HTT P42858 1/20 0.56
S1PR3 Q99500 1/20 0.56
MAPT P10636 6/20 0.54
RAB9A P51151 3/20 0.54
NPC1 O15118 2/20 0.54
SMN1; SMN2 Q16637 4/20 0.50
CYP1A2 P05177 6/20 0.49
CYP3A4 P08684 6/20 0.49
CYP2C9 P11712 6/20 0.49
CYP2C19 P33261 6/20 0.49
CYP2D6 P10635 5/20 0.49
ALDH1A1 P00352 5/20 0.49
TSHR P16473 3/20 0.49
TP53 P04637 1/20 0.49
ROCK2 O75116 4/20 0.49
ROCK1 Q13464 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6726556 0.83 PABPC1 (0.60) MEN1KMT2AHTTMAPTRAB9A
SCHEMBL6715920 0.82 POLB (0.61) MEN1KMT2ALMNAHTR1EHTT
SCHEMBL6715851 0.82 ALDH1A1 (0.59) MEN1KMT2ALMNAHTTMAPT
SCHEMBL6715868 0.82 CTSS (0.57) MEN1KMT2ALMNAHTR1EHTT
SCHEMBL25342412 0.81 RAB9A (0.56) MEN1KMT2ALMNAHTR1EHTT
SCHEMBL6716780 0.81 CRHBP (0.61) MEN1KMT2ALMNAMAPTRAB9A
SCHEMBL25342413 0.81 RAB9A (0.56) MEN1KMT2ALMNAHTR1EHTT
SCHEMBL6718828 0.80 ALDH1A1 (0.61) MEN1KMT2ALMNAHTR1EHTT
SCHEMBL6715528 0.79 HSD17B10 (0.53) MEN1KMT2ALMNAHTTMAPT
SCHEMBL6715776 0.79 KLK7 (0.61) MEN1KMT2ALMNAHTTMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040152741-A1 Arylglycine derivatives and their use as glycine transport inhibitors NPS ALLELIX CORPORATION (CA) 2004-08-05 US disclosed
WO-2004022528-A2 ARYLGLYCINE DERIVATIVES AND THEIR USE AS GLYCINE TRANSPORT INHIBITORS NPS ALLELIX CORP. (CA) 2004-03-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152741-A1 Arylglycine derivatives and their use as glycine transport inhibitors SLC1A2, SLC1A1, SLC7A11 MEN1 2822/4885KMT2A 1656/4885LMNA 3809/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.